Dr. Zelenetz on the Role of Biosimilars in Cancer Care

Andrew D. Zelenetz, MD, PhD
Published: Thursday, Mar 31, 2016

Andrew D. Zelenetz, MD, PhD, medical director, Quality Informatics, Memorial Sloan Kettering Cancer Center, discusses the role of biosimilars in cancer care. Zelenetz spoke about this topic at the 2016 NCCN Annual Conference.

Biosimilars will never outperform their ‘original’ counterparts, Zelenetz says. Biosimilars are meant to create competition and cost savings.

The NCCN is tasked with developing treatment guidelines regardless of cost. If guidelines can be followed at a lower cost—with biosimilars—this allows for continued innovation. Zelenetz says his talk was ideal for the audience because community oncologists will eventually be using biosimilars in their practices and they need to learn about them now.

<<< View more from the 2016 NCCN Annual Conference

Andrew D. Zelenetz, MD, PhD, medical director, Quality Informatics, Memorial Sloan Kettering Cancer Center, discusses the role of biosimilars in cancer care. Zelenetz spoke about this topic at the 2016 NCCN Annual Conference.

Biosimilars will never outperform their ‘original’ counterparts, Zelenetz says. Biosimilars are meant to create competition and cost savings.

The NCCN is tasked with developing treatment guidelines regardless of cost. If guidelines can be followed at a lower cost—with biosimilars—this allows for continued innovation. Zelenetz says his talk was ideal for the audience because community oncologists will eventually be using biosimilars in their practices and they need to learn about them now.

<<< View more from the 2016 NCCN Annual Conference


View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Community Practice Connections™: Medical Crossfire®: Translating Lessons Learned with PARP Inhibition to the Treatment of Breast Cancer—Expert Exchanges on Novel Strategies to Personalize CareAug 29, 20181.5
Community Practice Connections™: ALK-Positive NSCLC: Emerging Strategies to Inform Sequencing, Optimize Outcomes, and Address Unmet Clinical Needs Along the Disease ContinuumAug 29, 20181.5
Publication Bottom Border
Border Publication
x